Results 101 to 110 of about 6,425 (142)

Biomarkers for Predicting the Occurrence and Progression of Atrial Fibrillation: Soluble Suppression of Tumorigenicity 2 Protein and Tissue Inhibitor of Matrix Metalloproteinase-1. [PDF]

Int J Clin Pract, 2022
Sun WP, Du X, Chen JJ.
europepmc   +1 more source

Extracellular Vesicles: Classification, Biological Functions, Diseases, and Therapeutic Opportunities

MedComm, Volume 7, Issue 10, October 2026.
• EV content maintains cellular homeostasis and is involved in several disease onset and progression. • miRNA export in EVs depends on: RNA‐binding proteins recognizing motif sequences and on epitranscriptomic modifications. • The disclosure of delivery mechanisms is crucial for developing personalized EV‐based therapeutic tools. ABSTRACT Extracellular
Sabrina Garbo, Francesco Marocco, Clemens Zwergel, Marco Tripodi, Cecilia Battistelli   +4 more
wiley   +1 more source

Serum soluble suppression of tumorigenicity 2 as a novel inflammatory marker predicts the severity of acute pancreatitis. [PDF]

World J Gastroenterol, 2021
Zhang Y, Cheng B, Wu ZW, Cui ZC, Song YD, Chen SY, Liu YN, Zhu CJ.   +7 more
europepmc   +1 more source

Radiotherapy‐Induced Side Effects: Epidemiology, Pathogenesis, Prevention and Treatments

MedComm, Volume 7, Issue 10, October 2026.
Radiotherapy for malignancies frequently injures the organs’ systems through oxidative stress, fibrosis, inflammation, and vascular damage. This review systematically maps the epidemiology, pathogenesis, and emerging therapies to propose a mechanism‑network‑targeted framework for integrated, personalized care in radiation oncology.
Xiaowen Ma, Xiaoxuan Zhang, Pujun Zhao, Jiaxin Yang, Zhihao Li, Xiaoyang Han, Yixuan Wang, Zhenzhen Cui, Nian Liu, Min Li   +9 more
wiley   +1 more source

Diagnostic and prognostic value of serum soluble suppression of tumorigenicity-2 in heart failure with preserved ejection fraction: A systematic review and meta-analysis. [PDF]

Front Cardiovasc Med, 2022
Shi Y, Liu J, Liu C, Shuang X, Yang C, Qiao W, Dong G.   +6 more
europepmc   +1 more source

Ineffectiveness of immune checkpoint inhibitors in prostate cancer: is it just a question of ‘‐mabs’?

The Journal of Pathology, Volume 270, Issue 2, Page 139-162, October 2026.
Abstract Prostate cancer (PCa) is the second most common type of neoplasm, currently treated with a variety of therapeutic agents. Although advances in treatment over the past decade have improved overall survival, patients with advanced PCa eventually progress from hormone‐sensitive PCa to metastatic castration‐resistant PCa.
Giuseppe Schepisi, Irene Torresan, Emilio Francesco Giunta, Sara Bleve, Nicole Brighi, Elisa Tassinari, Sofia Zanuccoli, Maria Concetta Cursano, Cristian Lolli   +8 more
wiley   +1 more source

Extracellular Vesicles From Senescent Cancer Cells Are Necessary and Sufficient to Drive Paracrine Senescence

Aging Cell, Volume 25, Issue 10, October 2026.
Senescent cancer cells exhibit a secretory phenotype, known as SASP, capable of inducing paracrine senescence. However, the main factors within the SASP triggering this process are unknown. Here, we demonstrate that EVs within the SASP are necessary and sufficient to induce paracrine senescence.
Valentin Estevez‐Souto, Alex Miralles‐Dominguez, Pablo Pedrosa, Patricia Lado‐Fernandez, Miguel A. Prados, Alejandro Failde‐Fiestras, Raquel Paredes‐Paredes, Jorge Ruz‐Ortega, Maria J. Alonso, Martina Migliavacca, Ester Polo, Rebeca Alvarez‐Velez, Enrique Vazquez de Luis, Ana Dopazo, Gabriela N. Condezo, Carmen San Martin, Miguel Gonzalez‐Barcia, Ramón Lobato‐Busto, Pilar Ximénez‐Embún, Javier Muñoz, Manuel Collado, Sabela Da Silva‐Alvarez   +21 more
wiley   +1 more source

Development and validation of a multi-biomarker nomogram for baseline heart failure

European Journal of Medical Research
Purpose This study aimed to develop and validate a clinical-biomarker nomogram integrating heparin-binding protein (HBP), soluble suppression of tumorigenicity-2 (sST2), monocyte-to-lymphocyte ratio (MLR), and routine clinical variables for identifying ...
YuLin Liu, KeKe Ding, Bing Zhao, XiZhen Fan, ZiQiu Tang, HongQi Li, Li Chen   +6 more
doaj   +1 more source

Junctional Adhesion Molecule‐A (JAM‐A) Associates With High‐Risk Disease in Multiple Myeloma Patients and a Structure‐Based Rationally‐Designed Peptide Inhibitor Attenuates Tumorigenic Features In Vitro and In Vivo

European Journal of Haematology, Volume 117, Issue 4, Page 995-1006, October 2026.
ABSTRACT Multiple myeloma (MM) is an incurable malignancy of terminally‐differentiated plasma cells that represents a major clinical challenge despite unprecedented therapeutic advances, particularly for patients with cytogenetically‐defined high‐risk MM (HR‐MM).
Niamh McAuley, Roisin McAvera, Dimitri Bong, Lara Donnelly, Izabela Cymer, Marian Brennan, Joanna Fay, Lance Hudson, John Quinn, Siobhan V. Glavey, Ann M. Hopkins   +10 more
wiley   +1 more source

Plasma Soluble Suppression of Tumorigenicity-2 Associates with Ventilator Liberation in Acute Hypoxemic Respiratory Failure. [PDF]

Am J Respir Crit Care Med, 2021
Alladina J, Levy SD, Cho JL, Brait KL, Rao SR, Camacho A, Hibbert KA, Harris RS, Medoff BD, Januzzi JL, Thompson BT, Bajwa EK.   +11 more
europepmc   +1 more source